Přejít k obsahu
Merck
Všechny fotografie(1)

Key Documents

View All Documentation

1356960

USP

Leflunomide

United States Pharmacopeia (USP) Reference Standard

Synonyma:

5-Methylisoxazole-4-(4-trifluoromethyl)carboxanilide

Přihlásitk zobrazení cen stanovených pro organizaci a smluvních cen
Všechny fotografie(1)

About This Item

Empirický vzorec (Hillův zápis):
C12H9F3N2O2
Číslo CAS:
75706-12-6
Molekulová hmotnost:
270.21
MDL number:
MFCD00867593
UNSPSC Code:
41116107
PubChem Substance ID:
329750235
NACRES:
NA.24

grade

pharmaceutical primary standard

API family

leflunomide

manufacturer/tradename

USP

application(s)

pharmaceutical (small molecule)

format

neat

SMILES string

Cc1oncc1C(=O)Nc2ccc(cc2)C(F)(F)F

InChI

1S/C12H9F3N2O2/c1-7-10(6-16-19-7)11(18)17-9-4-2-8(3-5-9)12(13,14)15/h2-6H,1H3,(H,17,18)

InChI key

VHOGYURTWQBHIL-UHFFFAOYSA-N

Gene Information

human ... DHODH(1723)

Hledáte podobné produkty? Navštivte Průvodce porovnáváním produktů

General description

Leflunomide is a drug with cytotoxic properties. It is generally used as an immunosuppressive agent.

Application

Leflunomide USP reference standard, intended for use in specified quality tests and assays as specified in the USP compendia.

Analysis Note

These products are for test and assay use only. They are not meant for administration to humans or animals and cannot be used to diagnose, treat, or cure diseases of any kind.  ​

Other Notes

Sales restrictions may apply.

related product

Č. produktu
Popis
Stanovení ceny

Y0000654

Leflunomide, European Pharmacopoeia (EP) Reference Standard

Y0000674

Leflunomide for peak identification, European Pharmacopoeia (EP) Reference Standard

Y0000487

Leflunomide impurity A, European Pharmacopoeia (EP) Reference Standard

1357045

Leflunomide Related Compound A, United States Pharmacopeia (USP) Reference Standard

1357056

Leflunomide Related Compound B, United States Pharmacopeia (USP) Reference Standard

1357067

Leflunomide Related Compound C, United States Pharmacopeia (USP) Reference Standard

PHR1568

Leflunomide Related Compound A, Pharmaceutical Secondary Standard; Certified Reference Material

BP1233

Leflunomide, British Pharmacopoeia (BP) Reference Standard

PHR2878

Leflunomide Related Compound B, pharmaceutical secondary standard, certified reference material

pictograms

Skull and crossbones
GHS06

signalword

Danger

Hazard Classifications

Acute Tox. 3 Oral - Eye Irrit. 2 - Skin Irrit. 2 - STOT SE 3

target_organs

Respiratory system

Storage Class

6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects

wgk_germany

WGK 1

flash_point_f

Not applicable

flash_point_c

Not applicable

Osvědčení o analýze (COA)

Vyhledejte osvědčení Osvědčení o analýze (COA) zadáním čísla šarže/dávky těchto produktů. Čísla šarže a dávky lze nalézt na štítku produktu za slovy „Lot“ nebo „Batch“.

Již tento produkt vlastníte?

Dokumenty související s produkty, které jste v minulosti zakoupili, byly za účelem usnadnění shromážděny ve vaší Knihovně dokumentů.

Navštívit knihovnu dokumentů

Zákazníci si také prohlíželi

Slide 1 of 3

1 of 3

Teriflunomide ≥98% (HPLC)

Sigma-Aldrich

SML0936

Teriflunomide

Cephapirin sodium United States Pharmacopeia (USP) Reference Standard

USP

1102500

Cephapirin sodium

4-(Trifluoromethyl)aniline 99%

Sigma-Aldrich

224936

4-(Trifluoromethyl)aniline

S Greene et al.
Biochemical pharmacology, 50(6), 861-867 (1995-09-07)
Leflunomide [HWA 486 or RS-34821, 5-methyl-N-(4-trifluoromethylphenyl)-4-isoxazole carboximide] is an immunosuppressive agent effective in the treatment of rheumatoid arthritis. In spite of its clinical potential, its mechanism of action has not been elucidated. Recent studies suggest that leflunomide may interfere with
Robert P Baughman et al.
Sarcoidosis, vasculitis, and diffuse lung diseases : official journal of WASOG, 21(1), 43-48 (2004-05-07)
Leflunomide (Arava) is a cytotoxic drug which has been used as a single agent or in combination with methotrexate for the treatment of rheumatoid arthritis. It appears to have less toxicity than methotrexate. The use of leflunomide for sarcoidosis patients
Nicola Alcorn et al.
Drug safety, 32(12), 1123-1134 (2009-11-18)
Evidence is accumulating for the early sustained usage of disease-modifying anti-rheumatic drugs (DMARDs) in rheumatoid arthritis. Leflunomide was licensed for the treatment of rheumatoid arthritis in 1998. Postmarketing surveillance, case reports and observational studies have highlighted less common or unexpected
Frank Behrens et al.
Current opinion in rheumatology, 23(3), 282-287 (2011-03-24)
Leflunomide is often used as a first choice disease-modifying antirheumatic drug after methotrexate. New data are available for efficacy and safety in both, monotherapy and combination with biologicals. New data on efficacy demonstrate comparable effect sizes for leflunomide and methotrexate
W James Chon et al.
Expert review of clinical immunology, 7(3), 273-281 (2011-05-21)
Leflunomide is a synthetic isoxazole-derivative drug that possesses both immunosuppressive and antiviral properties. Although its only US FDA-approved indication is for the treatment of rheumatoid arthritis, accumulating clinical experience in addition to animal study data makes it an appealing option
Zobrazit všechny související dokumenty

Náš tým vědeckých pracovníků má zkušenosti ve všech oblastech výzkumu, včetně přírodních věd, materiálových věd, chemické syntézy, chromatografie, analytiky a mnoha dalších..

Obraťte se na technický servis.